ClinicalCodes.org
An online clinical codes repository to improve validity and reproducibility of medical database research
Research article:
Withdrawing Performance Indicators: Retrospective Analysis of General Practice Performance Under the UKs Quality and Outcomes Framework
Reference:
Kontopantelis, Evangelos; Springate, David; Reeves, David; Ashcroft, Darren; Valderas, Jose M; Doran, Tim(2014) Withdrawing Performance Indicators: Retrospective Analysis of General Practice Performance Under the UKs Quality and Outcomes Framework. British Medical Journal, doi: http://dx.doi.org/10.1136/bmj.g330
- Link to fulltext article
- Abstract
- Objectives: To investigate the effect of withdrawing incentives on recorded quality of care, in the context of the UK Quality and Outcomes Framework pay-for-performance scheme. Design: Retrospective longitudinal study. Setting: Data for 644 general practices, from 2004/5 to 2011/12, extracted from the Clinical Practice Research Datalink. Participants: All patients registered with any of the practices over the study period, 13,772,992 in total. Intervention: The removal of financial incentives for aspects of care for patients with asthma, coronary heart disease, diabetes, stroke and psychosis. Main outcome measures: Performance on eight clinical quality indicators withdrawn from a national incentive scheme: influenza immunisation (asthma) and lithium therapy monitoring (psychosis), removed in April 2006; blood pressure monitoring (coronary heart disease, diabetes, stroke), cholesterol level monitoring (coronary heart disease, diabetes) and blood glucose monitoring (diabetes), removed in April 2011. Multilevel mixed effects multiple linear regression models were used to quantify the effect of incentive withdrawal. Results: Mean levels of performance were generally stable after the removal of the incentives, both short- and long-term. For the two indicators removed in April 2006/7, levels in 2011/12 were very close to 2005/6 levels, although a small but statistically significant drop was estimated for influenza immunisation. For five of the six indicators withdrawn in from April 2011/12, there was no significant impact on performance in that year following removal and differences between predicted and observed scores were small. Performance on related outcome indicators retained in the scheme (e.g. blood pressure control) was generally unaffected. Conclusions: Following the removal of incentives, levels of performance across a range of clinical activities generally remained stable. This indicates that health benefits from incentive schemes can potentially be increased by periodically replacing existing indicators with new indicators relating to alternative aspects of care. However, most of the aspects of care we investigated remained indirectly incentivised and further work is required to assess the generalisability of the findings when incentives are fully withdrawn.
- Author for correspondence
- Evangelos Kontopantelis
- Email for correspondence
- e.kontopantelis@manchester.ac.uk
Code list: spirometry
14 codes in list
| Code | Coding system | Description | Entity type | List name | |||
|---|---|---|---|---|---|---|---|
| 33G..00 | Read | Spirometry reversibility | test | spirometry | |||
| 33G0.00 | Read | Spirometry reversibility negative | test | spirometry | |||
| 33G1.00 | Read | Spirometry reversibility positive | test | spirometry | |||
| 33H..00 | Read | Salbutamol reversibility | test | spirometry | |||
| 33H0.00 | Read | Negative reversibility test to salbutamol | test | spirometry | |||
| 33H1.00 | Read | Positive reversibility test to salbutamol | test | spirometry | |||
| 33I..00 | Read | Ipratropium reversibility | test | spirometry | |||
| 33I0.00 | Read | Negative reversibility test to ipratropium bromide | test | spirometry | |||
| 33I1.00 | Read | Positive reversibility test to ipratropium bromide | test | spirometry | |||
| 33J..00 | Read | Combined reversibility | test | spirometry | |||
| 33J0.00 | Read | Neg reversibil test to combinat of salbutamol + ipratrop br | test | spirometry | |||
| 33J1.00 | Read | Pos reversib test to combin of salbutamol + ipratropium br | test | spirometry | |||
| 66Ya.00 | Read | Reversibility trial by bronchodilator | test | spirometry | |||
| 66Yb.00 | Read | Reversibility trial by anticholinergic | test | spirometry |
Please log in to leave a comment.
Code list links:
ClinicalCodes is a project at the University of Manchester Institute of Population Health
The ClinicalCodes project is funded by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR)
Codes used to identify patients achieving QOF indicators ASTHMA 2, COPD 2